Circulating miRNAs as new blood-based biomarkers for solid
cancers

J 2013

Circulating miRNAs as new blood-based biomarkers for solid cancers

RÉDOVÁ, Martina; Jiří ŠÁNA a Ondřej SLABÝ

Základní údaje

Originální název

Circulating miRNAs as new blood-based biomarkers for solid cancers

Autoři

RÉDOVÁ, Martina; Jiří ŠÁNA a Ondřej SLABÝ

Vydání

Future Oncology, London, Future Medicine Ltd. 2013, 1479-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.611

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/13:00065587

Organizační jednotka

Středoevropský technologický institut

DOI

https://doi.org/10.2217/FON.12.192

UT WoS

000315966900013

Klíčová slova anglicky

biomarkers; breast cancer; colorectal cancer; lung cancer; miRNA; plasma; prostate cancer; serum

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 4. 2014 00:51, Olga Křížová

Anotace

V originále

miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13549, projekt VaV

Název: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem

Citovat

RÉDOVÁ, Martina; Jiří ŠÁNA a Ondřej SLABÝ. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncology. London: Future Medicine Ltd., 2013, roč. 9, č. 3, s. 387-402, 6 s. ISSN 1479-6694. Dostupné z: https://doi.org/10.2217/FON.12.192.

@article{1103755,
   author = {Rédová, Martina and Šána, Jiří and Slabý, Ondřej},
   article_location = {London},
   article_number = {3},
   doi = {https://doi.org/10.2217/FON.12.192},
   keywords = {biomarkers; breast cancer; colorectal cancer; lung cancer; miRNA; plasma; prostate cancer; serum},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Circulating miRNAs as new blood-based biomarkers for solid cancers},
   volume = {9},
   year = {2013}
}

TY  - JOUR
ID  - 1103755
AU  - Rédová, Martina - Šána, Jiří - Slabý, Ondřej
PY  - 2013
TI  - Circulating miRNAs as new blood-based biomarkers for solid cancers
JF  - Future Oncology
VL  - 9
IS  - 3
SP  - 387-402
EP  - 387-402
PB  - Future Medicine Ltd.
SN  - 14796694
KW  - biomarkers
KW  - breast cancer
KW  - colorectal cancer
KW  - lung cancer
KW  - miRNA
KW  - plasma
KW  - prostate cancer
KW  - serum
N2  - miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.
ER  -

RÉDOVÁ, Martina; Jiří ŠÁNA a Ondřej SLABÝ. Circulating miRNAs as new blood-based biomarkers for solid cancers. \textit{Future Oncology}. London: Future Medicine Ltd., 2013, roč.~9, č.~3, s.~387-402, 6 s. ISSN~1479-6694. Dostupné z: https://doi.org/10.2217/FON.12.192.

Přehled o publikaci